We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Healthy receptions

23 Jun 2004 By Robert Cyran

The successful float of Czech generic drug company Zentiva shows investors have some appetite for growth. But while IPOs of stable companies such as Biomerieux should get a warm reception, signs are higherrisk biotechs won t.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)